Search Browse Earnings

ENANTA PHARMACEUTICALS INC

Nasdaq:ENTA

Pharmaceutical Preparations·WATERTOWN, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

ENANTA PHARMACEUTICALS INC — SlamSEC

Revenue

$79.2M

-8.1% YoY

FY 2025

Adj. EBITDA

-$134.8M

-170.2% margin

FY 2025

Net Income

-$133.8M

-169.0% margin

FY 2025

EPS (Diluted)

-$6.38

FY 2025

Stock Price

$13.54

-1.6%

2026-03-06

52W Range

$4.09 – $17.15

P/E Ratio

-2.1x

Market Cap

$392.9M

Cash

$37.2M

FY 2025

Total Debt

—

Net Cash

$37.2M

FY 2025

Enterprise Value

$355.7M

Debt / EBITDA

0.3x

FY 2025

EV / EBITDA

-2.6x

Employees

—

CEO

Luly Jay R.